ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)

ClinicalTrials.gov ID: NCT03217136

Public ClinicalTrials.gov record NCT03217136. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 3:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem in Pediatric Subjects With Complicated Intra-Abdominal Infection

Study identification

NCT ID
NCT03217136
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Enrollment
94 participants

Conditions and interventions

Interventions

  • Ceftolozane/Tazobactam Drug
  • Meropenem Drug
  • Metronidazole Drug
  • Placebo for Metronidazole Drug

Drug

Eligibility (public fields only)

Age range
7 Days to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 2, 2018
Primary completion
Mar 15, 2020
Completion
Mar 15, 2020
Last update posted
May 5, 2023

2018 – 2020

United States locations

U.S. sites
9
U.S. states
7
U.S. cities
9
Facility City State ZIP Site status
Children's Hospital - Los Angeles ( Site 2508) Los Angeles California 90027
Children's Hospital of Orange County ( Site 2502) Orange California 92868
Rady Children's Hospital-San Diego ( Site 2505) San Diego California 92123
Baptist Medical Center/Wolfson Children's Hospital ( Site 2521) Jacksonville Florida 32207
Tufts Medical Center-Floating Hospital for Children ( Site 2516) Boston Massachusetts 02111
St. Louis Children's Hospital ( Site 2511) St Louis Missouri 63110
SUNY Upstate Medical University Hospital ( Site 2509) Syracuse New York 13210
Primary Children's Hospital ( Site 2500) Salt Lake City Utah 84113
Seattle Childrens Hospital ( Site 2510) Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03217136, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 5, 2023 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03217136 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →